CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

NCT03233854 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
CD19 Positive
Minimal Residual Disease
Philadelphia Chromosome Positive

Interventions

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy
DRUG: Cyclophosphamide
DRUG: Fludarabine Phosphate
OTHER: Laboratory Biomarker Analysis
OTHER: Questionnaire Administration
DRUG: NKTR-255

Sponsor

Stanford University

Collaborators

[object Object]